Natera, Inc. (NASDAQ:NTRA) CFO Sells $4,277,837.07 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 25,931 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,277,837.07. Following the sale, the chief financial officer now directly owns 109,665 shares of the company’s stock, valued at approximately $18,091,435.05. This trade represents a 19.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total value of $162,693.08.
• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total value of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $146,343.98.
• On Friday, October 25th, Michael Burkes Brophy sold 691 shares of Natera stock. The stock was sold at an average price of $118.81, for a total value of $82,097.71.

Natera Trading Down 2.5 %

Natera stock opened at $167.61 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a one year low of $62.96 and a one year high of $183.00. The stock has a market capitalization of $22.13 billion, a PE ratio of -95.23 and a beta of 1.65. The business’s fifty day moving average is $166.20 and its 200 day moving average is $136.07.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s revenue for the quarter was up 63.9% on a year-over-year basis. During the same period last year, the firm posted ($0.95) earnings per share. On average, sell-side analysts predict that Natera, Inc. will post -1.56 EPS for the current year.

Institutional Trading of Natera

Large investors have recently added to or reduced their stakes in the business. Chartwell Investment Partners LLC boosted its stake in shares of Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after acquiring an additional 11,362 shares during the last quarter. Cerity Partners LLC lifted its position in Natera by 27.0% during the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after purchasing an additional 18,316 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Natera during the third quarter valued at about $385,000. Everence Capital Management Inc. bought a new stake in Natera during the fourth quarter valued at about $573,000. Finally, First Turn Management LLC purchased a new stake in Natera in the third quarter worth about $19,760,000. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on NTRA shares. Robert W. Baird raised their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. raised their price target on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. The Goldman Sachs Group increased their price objective on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Finally, Canaccord Genuity Group increased their price objective on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $162.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.